Mabpharm Limited (2181.HK)

HKD 0.3

(-4.76%)

Total Liabilities Summary of Mabpharm Limited

Mabpharm Limited's latest annual total liabilities in 2023 was 829.91 Million CNY , up 60.66% from previous year.
Mabpharm Limited's latest quarterly total liabilities in 2024 Q2 was 831.2 Million CNY , down 0.0% from previous quarter.
Mabpharm Limited reported annual total liabilities of 516.57 Million CNY in 2022, up 73.39% from previous year.
Mabpharm Limited reported annual total liabilities of 297.92 Million CNY in 2021, up 5.81% from previous year.
Mabpharm Limited reported quarterly total liabilities of 831.2 Million CNY for 2024 Q2, down 0.0% from previous quarter.
Mabpharm Limited reported quarterly total liabilities of 829.91 Million CNY for 2023 Q3, up 39.17% from previous quarter.

Annual Total Liabilities Chart of Mabpharm Limited (2023 - 2017)

Historical Annual Total Liabilities of Mabpharm Limited (2023 - 2017)

Year	Total Liabilities	Total Liabilities Growth
2023	829.91 Million CNY	60.66%
2022	516.57 Million CNY	73.39%
2021	297.92 Million CNY	5.81%
2020	281.55 Million CNY	-17.86%
2019	342.76 Million CNY	53.26%
2018	223.65 Million CNY	64.63%
2017	135.85 Million CNY	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q1	831.2 Million CNY	0.16%
2024 Q2	831.2 Million CNY	0.0%
2023 Q3	829.91 Million CNY	39.17%
2023 Q2	596.32 Million CNY	0.0%
2023 Q1	596.32 Million CNY	15.44%
2023 Q4	829.91 Million CNY	0.0%
2023 FY	829.91 Million CNY	60.66%
2022 Q1	446.87 Million CNY	50.0%
2022 FY	516.57 Million CNY	73.39%
2022 Q3	516.57 Million CNY	15.6%
2022 Q2	446.87 Million CNY	0.0%
2022 Q4	516.57 Million CNY	0.0%
2021 FY	297.92 Million CNY	5.81%
2021 Q4	297.92 Million CNY	0.0%
2021 Q3	297.92 Million CNY	26.38%
2021 Q1	235.73 Million CNY	-16.27%
2021 Q2	235.73 Million CNY	0.0%
2020 Q4	281.55 Million CNY	0.0%
2020 FY	281.55 Million CNY	-17.86%
2020 Q2	310.88 Million CNY	0.0%
2020 Q1	310.88 Million CNY	-9.3%
2020 Q3	281.55 Million CNY	-9.43%
2019 Q1	273.55 Million CNY	22.31%
2019 FY	342.76 Million CNY	53.26%
2019 Q4	342.76 Million CNY	0.0%
2019 Q3	342.76 Million CNY	25.3%
2019 Q2	273.55 Million CNY	0.0%
2018 FY	223.65 Million CNY	64.63%
2018 Q1	- CNY	0.0%
2018 Q4	223.65 Million CNY	0.0%
2018 Q3	223.65 Million CNY	0.0%
2017 FY	135.85 Million CNY	0.0%

Peer Total Liabilities Comparison of Mabpharm Limited

Name	Total Liabilities	Total Liabilities Difference
Uni-Bio Science Group Limited	152.81 Million HKD	-443.075%
CK Life Sciences Int'l., (Holdings) Inc.	7.05 Billion HKD	88.242%